Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
BLCO(NYSE:BLCO) VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of XIIDRA (lifitegrast ophthalmic solution) 5% in alleviating end-of-day (EOD) eye dryness and discomfort in symptomatic contact lens (CL) wearers.* XIIDRA is a prescription eye drop used to treat
Bausch + Lomb Announces Board Changes
BLCOVAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the Icahn group’s net long position in the common shares of Bausch + Lomb’s parent company, B
Bausch + Lomb to Participate in Upcoming Investor Conferences
BLCOVAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Morgan Stanley Global Healthcare Conference September 8, 2025, 7:45 a.m. ET, New York, NY Executive Vice President and Chief Financial O
Bausch + Lomb Subsidiaries Launch Offering Of €600M Aggregate Principal Amount Of Senior Secured Floating Rate Notes
BLCOBarclays Maintains Equal-Weight on Bausch & Lomb, Lowers Price Target to $16
BLCOBausch + Lomb Announced The U.S. Launch Of Blink Nourish Lubricating Eye Drops And Blink Boost Lubricating Eye Drops
BLCOBausch + Lomb Announced The U.S. Launch Of LUMIFY Preservative Free Redness Reliever Eye Drops, The First And Only Preservative-free Over-the-counter Eye Drops With Low-dose Brimonidine Tartrate 0.025% That Relieve Redness Of The Eye Due To Minor Eye Irri
BLCOBausch + Lomb Announced The U.S. Launch Of Zenlens Chroma Hoa Scleral Contact Lenses
BLCOBausch + Lomb Wins CE Mark for LuxLife Lens, Offering Patients Full-Range Vision
BLCOMorgan Stanley Maintains Equal-Weight on Bausch & Lomb, Lowers Price Target to $12
BLCOHC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $15
BLCOCitigroup Maintains Neutral on Bausch & Lomb, Lowers Price Target to $13
BLCOWells Fargo Maintains Equal-Weight on Bausch & Lomb, Lowers Price Target to $12
BLCOEvercore ISI Group Maintains Outperform on Bausch & Lomb, Lowers Price Target to $15.5
BLCOStarbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
BLCOBausch & Lomb Raises FY2025 Sales Guidance from $4.95B-$5.05B to $5.00B-$5.10B vs $5.01B Est
BLCOBausch & Lomb Q1 Adj. EPS $(0.07) Misses $0.03 Estimate, Sales $1.14B Miss $1.15B Estimate
BLCONeedham Reiterates Hold on Bausch & Lombto Hold
BLCOBausch + Lomb To Resume enVista IOL Distribution After Identifying Cause Behind Voluntary Recall
BLCOBausch + Lomb's ONE By ONE And Biotrue Eye Care Recycling Programs Collect Over 100M Units Of Used Materials
BLCORBC Capital Maintains Outperform on Bausch & Lomb, Lowers Price Target to $17
BLCOStifel Maintains Hold on Bausch & Lomb, Lowers Price Target to $15
BLCOWells Fargo Downgrades Bausch & Lomb to Equal-Weight, Lowers Price Target to $15
BLCOBausch + Lomb Reveals US Launch Of Arise Lens Fitting System
BLCOHC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $20
BLCORBC Capital Maintains Outperform on Bausch & Lomb, Lowers Price Target to $18
BLCOB of A Securities Maintains Underperform on Bausch & Lomb, Lowers Price Target to $17
BLCONeedham Reiterates Hold on Bausch & Lombto Hold
BLCOBausch + Lomb Sees FY25 Revenue Of $4.950B - $5.050B Vs. $5.02B Est.
BLCOBausch & Lomb Q4 Adj $0.25 Beats $0.24 Estimate, Sales $1.28B Beat $1.26B Estimate
BLCOHC Wainwright & Co. Reiterates Buy on Bausch & Lomb, Maintains $23 Price Target
BLCOLive On CNBC, Bausch + Lomb CEO Discusses Sale Rumors, Shares See Volume To The Upsde
BLCOBausch + Lomb Affiliate Acquires Whitecap Biosciences, LLC; No Terms Disclosed
BLCOCitigroup Maintains Buy on Bausch & Lomb, Raises Price Target to $24
BLCOWells Fargo Maintains Overweight on Bausch & Lomb, Raises Price Target to $26
BLCOHC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $23
BLCONeedham Reiterates Hold on Bausch & Lomb
BLCOWhat 4 Analyst Ratings Have To Say About Bausch & Lomb
BLCOBausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:
Expert Ratings for Bausch & Lomb
BLCOWithin the last quarter, Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings:
HC Wainwright & Co. Initiates Coverage On Bausch & Lomb with Buy Rating, Announces Price Target of $21
BLCO